Breast Conservation Increases With On-Site Radiation Unit

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 1
Volume 11
Issue 1

SAN FRANCISCO-The rate of breast-conserving surgery with adjuvant radiation therapy increased at a North Carolina community hospital (Durham Regional) after Duke University Medical Center radiation oncologists opened an on-site clinic. The study results were presented at the 43rd Annual Meeting of the American Society for Therapeutic Radiology and Oncology (abstract 87).

SAN FRANCISCO—The rate of breast-conserving surgery with adjuvant radiation therapy increased at a North Carolina community hospital (Durham Regional) after Duke University Medical Center radiation oncologists opened an on-site clinic. The study results were presented at the 43rd Annual Meeting of the American Society for Therapeutic Radiology and Oncology (abstract 87).

During the period when the radiation oncology clinic was located 5 miles from the community hospital, the rate of breast-conserving therapy was only 28.7%, said lead investigator Carol Hahn, MD, associate professor of radiation oncology at Duke and chief of the Division of Radiation Oncology at Durham Regional. After the radiation oncology clinic moved into the hospital, the incidence of breast-conserving therapy shot up to 43.7%.

Previous studies have shown that the rate of breast-conserving therapy is influenced by several variables, including patient age, insurance coverage, and geographic location. Why do such nonmedical variables influence therapy for breast conservation, the preferred treatment for many women with early breast cancer? Dr. Hahn asked. "We had a change in practice setting that allowed us to gain some insight into this," she said.

The Comparison

The researchers examined the community hospital’s pathology database to compare treatment of 262 breast cancer patients during 1994-1995 when radiotherapy was provided at Duke and 304 breast cancer patients during 1997-1998 after the move to the community hospital. Multivariate analysis revealed that the incidence of breast-conserving therapy increased significantly (P < .001) after the clinic moved on-site.

The incidence of breast-conserving therapy for patients with ductal carcinoma in situ (DCIS) did not change during the study and was much higher during both periods than for women with invasive cancer.

Dr. Hahn reported that the incidence of breast-conserving therapy in patients with invasive disease increased from approximately 21% before the move to 44% afterwards.

"The effect of a 5-mile distance was much greater than we would have predicted," Dr. Hahn said. "There was no change in demographics that we know of. There was no change in staffing, either from the radiation therapy side or the surgical side."

Dr. Hahn postulated that the increased incidence of breast-conserving therapy after moving the radiotherapy clinic on-site may have been due to increased interactions between radiation oncologists and hospital physicians.

"Obviously, we felt that we were very accessible being only 5 miles down the road, but greater accessibility did increase the rate of breast conservation. Perhaps we should look at our referral systems, to see how patients are brought into tertiary care to ensure that we really are as accessible as we think we are," Dr. Hahn concluded.

Related Videos
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Related Content